Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6912953 | 0.81 | KDM1A (0.61) | KDM1AALDH1A1 | |
| SCHEMBL8230316 | 0.81 | PARP1 (0.50) | KDM4EALDH1A1L3MBTL1GRIN2DGRIN3B | |
| SCHEMBL5666139 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1L3MBTL1FURINGRIN2D | |
| SCHEMBL5666137 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1L3MBTL1FURINGRIN2D | |
| SCHEMBL9938975 | 0.76 | KDM1A (0.60) | KDM1AKDM4EALDH1A1L3MBTL1FURIN | |
| SCHEMBL21215365 | 0.76 | KDM1A (0.60) | KDM1AKDM4EALDH1A1L3MBTL1FURIN | |
| SCHEMBL9938969 | 0.76 | KDM1A (0.60) | KDM1AKDM4EALDH1A1L3MBTL1FURIN | |
| SCHEMBL935785 | 0.76 | UNG (0.63) | L3MBTL1 | |
| SCHEMBL2165506 | 0.76 | UNG (0.63) | L3MBTL1 | |
| SCHEMBL6923784 | 0.76 | UNG (0.63) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2021-10-28 | — | — | US | disclosed |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2020-12-10 | — | — | US | disclosed |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-01-03 | — | — | US | disclosed |
| US-9937175-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9469627-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2016-10-18 | — | — | US | disclosed |
| US-9469627-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2016-10-18 | — | — | US | disclosed |
| EP-2486024-B1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| WO-2011044307-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 2085/4885KDM4E 3936/4885ALDH1A1 613/4885 |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 2085/4885KDM4E 3936/4885ALDH1A1 613/4885 |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 2028/4885KDM4E 3920/4885ALDH1A1 609/4885 |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 2085/4885KDM4E 3936/4885ALDH1A1 613/4885 |
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 2085/4885KDM4E 3936/4885ALDH1A1 613/4885 |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 1927/4885KDM4E 3914/4885ALDH1A1 545/4885 |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | KDM1A 2085/4885KDM4E 3936/4885ALDH1A1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.